Adenocarcinoma Of Esophagus: all 354 studies

Page 2 of 4. Open to participants first (81), then studies with results posted, then the rest; newest registration first within each.

• A Minimally-Invasive Sponge on a String Device for Screening for Barrett's EsophagusCompletedNCT02560623Not applicableResults posted
• Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction CancerTerminatedNCT02530437Phase 1/2Results posted
• Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency AblationActive, not recruitingNCT02521285Phase 2Results posted
• Trial to Assess the Effects of an Antimicrobial Mouthwash on the Esophageal MicrobiomeCompletedNCT02513784Not applicableResults posted
• Molecular Phenotyping in Predicting Response in Patients With Stage IB-III Esophageal Cancer Receiving Combination ChemotherapyTerminatedNCT02392377Phase 2Results posted
• Regorafenib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Who Have Completed Chemoradiation Therapy and SurgeryTerminatedNCT02234180Phase 2Results posted
• Esophageal Cytology With FISH in Detecting Esophageal CancerCompletedNCT02100189Not applicableResults posted
• Evaluate Esophageal Reinforcement With ACell MatriStem Surgical Matrix: A Degradable Biologic Scaffold MaterialCompletedNCT01970306Phase 2Results posted
• Spray Cryotherapy for Esophageal Cancer (ICE-CANCER)TerminatedNCT01868139Not applicableResults posted
• Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by SurgeryCompletedNCT01612546Phase 2Results posted
• S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction CancerCompletedNCT01498289Phase 2Results posted
• Lapatinib With Carboplatin and Paclitaxel in Esophagus and Gastroesophageal Junction (GEJ)TerminatedNCT01395537Phase 1/2Results posted
• Neoadjuvant Chemotherapy Versus Radiochemotherapy for Cancer of the Esophagus or CardiaCompletedNCT01362127Phase 2Results posted
• PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination ChemotherapyCompletedNCT01333033Phase 2Results posted
• Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction CancerTerminatedNCT01307956Phase 2Results posted
• Trial of a Gastrin Receptor Antagonist in Barrett's EsophagusCompletedNCT01298999Phase 2Results posted
• Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal CancerCompletedNCT01231399Phase 1/2Results posted
• Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach CancerCompletedNCT01212822Phase 2Results posted
• Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal CancerCompletedNCT01196390Phase 3Results posted
• Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction CancerCompletedNCT01178944Phase 2Results posted
• Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction CancerActive, not recruitingNCT01142388Phase 2Results posted
• Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based TherapyCompletedNCT01129206Phase 2Results posted
• Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach CancerCompletedNCT00985192Phase 2Results posted
• Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal JunctionCompletedNCT00938470Phase 2Results posted
• Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal JunctionCompletedNCT00891878Phase 2Results posted
• Phase II Study of Irinotecan and PanitumumabCompletedNCT00836277Phase 2Results posted
• Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal JunctionCompletedNCT00757172Phase 2Results posted
• Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Esophageal or Gastroesophageal Junction CancerCompletedNCT00711412Phase 2Results posted
• Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal AdenocarcinomaTerminatedNCT00667420Phase 1/2Results posted
• Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or StomachCompletedNCT00601705Phase 2Results posted
• Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric CardiaCompletedNCT00591123Phase 2Results posted
• Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal CancerTerminatedNCT00573131Phase 2Results posted
• Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction CancerTerminatedNCT00551759Phase 2Results posted
• Erlotinib and Radiation Therapy in Treating Older Patients With Stage I, Stage II, Stage III, or Stage IV Esophageal CancerCompletedNCT00524121Phase 2Results posted
• Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By SurgeryTerminatedNCT00493025Phase 2Results posted
• Confocal Endomicroscopy for Barrett's EsophagusCompletedNCT00487695Phase 3Results posted
• Oxaliplatin, Capecitabine, and Radiation Therapy in Patients Undergoing Surgery for Stage II, III, IV Esophageal CancerCompletedNCT00470184Phase 2Results posted
• Combination Chemotherapy in Treating Patients With Previously Untreated Stage II or Stage III Esophageal Cancer That Can Be Removed By SurgeryCompletedNCT00448760Phase 2Results posted
• Preoperative Capecitabine, Oxaliplatin, Cetuximab, and Radiation Therapy for Locally Advanced Esophageal AdenocarcinomaTerminatedNCT00430027Not applicableResults posted
• Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and CisplatinCompletedNCT00397904Phase 2Results posted
• Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction CancerCompletedNCT00381706Phase 2Results posted
• Irinotecan, Cisplatin, Bevacizumab, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Esophageal CancerCompletedNCT00354679Phase 2Results posted
• Cisplatin, Irinotecan, and Radiation Therapy in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By SurgeryCompletedNCT00316862Phase 2Results posted
• Radiation Therapy, Pemetrexed Disodium, and Carboplatin in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed By SurgeryTerminatedNCT00268437Phase 2Results posted
• Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction CancerCompletedNCT00268346Phase 2Results posted
• S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal CancerTerminatedNCT00109850Phase 2Results posted
• S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction CancerCompletedNCT00096031Phase 2Results posted
• S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) JunctionCompletedNCT00086996Phase 2Results posted
• Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal JunctionCompletedNCT00069953Phase 2Results posted
• A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction CancerTerminatedNCT00064259Phase 1/2Results posted
• Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal CancerCompletedNCT00052910Phase 3Results posted
• Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal CancerCompletedNCT00033657Phase 2Results posted
• Antineoplaston Therapy in Treating Patients With Cancer of the EsophagusTerminatedNCT00003487Phase 2Results posted
• Evaluation of Esophagogastric Cancer Treatment With Nivolumab in Daily Clinical PracticeActive, not recruitingNCT07663786
• Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal AdenocarcinomasActive, not recruitingNCT07546812Phase 2
• Trans-Oral Sampling as an Alternative Surveillance of Barrett's Esophagus PilotActive, not recruitingNCT07490340
• A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D MutationActive, not recruitingNCT07023731Phase 1/2
• Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid TumorsActive, not recruitingNCT07021066Phase 1
• Molecular Analysis of Gastric and OEsophageal Cancers STudyWithdrawnNCT06702384
• Oncometabolome and MALDI-MSI in Upper GI Carcinomas - Chemosensitivity in Esophageal CarcinomaActive, not recruitingNCT06642506
• A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal AdenocarcinomaActive, not recruitingNCT06628310Phase 2
• A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 MutationTerminatedNCT06560645Phase 1
• A Study of SGN-B6A in Chinese Participants With Advanced Solid TumorsCompletedNCT06549816Phase 1
• Observational Study of Patients Treated With Nivolumab and Chemotherapy for Advanced or Metastatic Esophageal, Gastroesophageal or Gastric Cancer in FranceActive, not recruitingNCT06504615
• A Liquid Biopsy for High-risk Pre-cancer Screening of Esophageal AdenocarcinomaCompletedNCT06381583
• A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)Active, not recruitingNCT06356311Phase 3
• A Study of KK2269 in Adult Participants With Solid TumorsActive, not recruitingNCT06266299Phase 1
• A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction CancerActive, not recruitingNCT06251973Phase 2
• CLUE: CLinical Utility Study of EsoGuardCompletedNCT06030180Not applicable
• A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors.TerminatedNCT05977322Phase 1
• Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid TumorsActive, not recruitingNCT05945823Phase 2
• Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical SurgeryActive, not recruitingNCT05713838Phase 2
• Public's Intended Uptake and Views on Organization of Esophageal Cancer ScreeningStatus unknownNCT05690958
• A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the BodyCompletedNCT05568095Phase 3
• The Microbiome, Bile Acids, and Notch in Barrett's Esophagus (BE)CompletedNCT05524844
• Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal JunctionActive, not recruitingNCT05480384Phase 2
• Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction CancerActive, not recruitingNCT05476796Phase 2
• Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer PatientsCompletedNCT05411133Phase 1
• Clinical Study of Regorafenib and Nivolumab Plus ChemotherapyCompletedNCT05394740Phase 1/2
• A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract MalignanciesCompletedNCT05329766Phase 2
• (VELA) Study of BLU-222 in Advanced Solid TumorsTerminatedNCT05252416Phase 1
• A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersActive, not recruitingNCT05152147Phase 3
• Combination of Capmatinib + Spartalizumab in Advanced Oesogastric AdenocarcinomaSuspendedNCT05135845Phase 2
• Preoperative Marking of the Oral Resection Margin in Esophageal Cancer With a Surgical Fiducial Marker - First ExperiencesCompletedNCT05069766Not applicable
• Circulating Tumor DNA (ctDNA) in Locally Advanced Esophageal and Gastroesophageal (GE) Junction AdenocarcinomaWithdrawnNCT05067842
• Endoscopic Radiofrequency Ablation Versus Hybrid Argon Plasma Coagulation in the Treatment of Barrett's EsophagusCompletedNCT05051475Not applicable
• Study of FMT Combined With Nivolumab in Gastric CancerWithdrawnNCT05001360Not applicable
• Outcomes of Endoscopically Resected High-risk Mucosal and Low- and High-risk Submucosal Adenocarcinoma Arising in Barrett's EsophagusStatus unknownNCT04818476
• Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing TumorsActive, not recruitingNCT04802876Phase 2
• Urokinase-type Plasminogen Activator Receptor and Gastroesophageal CancerCompletedNCT04669951Not applicable
• Nitrates and IL-8 in Barrett's EsophagusTerminatedNCT04642690
• Blood-borne Assessment of Stromal Activation in Esophageal Adenocarcinoma to Guide Tocilizumab TherapyActive, not recruitingNCT04554771Phase 2
• Survey Study on Barrett's Esophagus ScreeningCompletedNCT04408105
• Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EACActive, not recruitingNCT04295811Not applicable
• Efficacy of EsoGuard on Samples Collected Using EsoCheck Versus EGD for the Diagnosis of BECompletedNCT04293458Not applicable
• Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the BodyActive, not recruitingNCT04248452Phase 3
• Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)CompletedNCT04210115Phase 3
• Maintaining Fitness During Neo-adjuvant Chemotherapy for Oesophago-gastric Cancer: a Feasibility StudyStatus unknownNCT04194463Not applicable
• RICE: Radio-Immuno-Chemotherapy of Cancer of the EsophagusActive, not recruitingNCT04159974Phase 2
• GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic AdenocarcinomaTerminatedNCT04060342Phase 1

← Adenocarcinoma Of Esophagus overview